Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities.
Aligos Therapeutics has raised $105.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in February 2025.
Aligos Therapeutics's investors include Wellington Management, Vivo Capital, Janus Henderson Investors, Cormorant Asset Management, Novo Holdings.
Aligos Therapeutics is headquartered in San Francisco, United States.
Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities.
Aligos Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Aligos Therapeutics — Funding & Investors." VCBacked, February 12, 2025, https://www.vcbacked.co/company/aligos-therapeutics. Accessed September 17, 2026.
VCBacked. (2025). Aligos Therapeutics — Funding & Investors. Retrieved September 17, 2026, from https://www.vcbacked.co/company/aligos-therapeutics
{{cite web |title=Aligos Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/aligos-therapeutics |website=VCBacked |access-date=September 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated